JPWO2022125908A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022125908A5 JPWO2022125908A5 JP2023534646A JP2023534646A JPWO2022125908A5 JP WO2022125908 A5 JPWO2022125908 A5 JP WO2022125908A5 JP 2023534646 A JP2023534646 A JP 2023534646A JP 2023534646 A JP2023534646 A JP 2023534646A JP WO2022125908 A5 JPWO2022125908 A5 JP WO2022125908A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyldiyl
- immunoconjugate
- peg
- alkyl
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940127121 immunoconjugate Drugs 0.000 claims 40
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- -1 proline amino acid Chemical class 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 8
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 8
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 8
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 8
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 8
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 8
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 8
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 8
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 7
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 150000001413 amino acids Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000004452 carbocyclyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000006693 (C2-C9) heterocyclyl group Chemical group 0.000 claims 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 125000006519 CCH3 Chemical group 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229940097043 glucuronic acid Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124396P | 2020-12-11 | 2020-12-11 | |
| US63/124,396 | 2020-12-11 | ||
| PCT/US2021/062824 WO2022125908A1 (en) | 2020-12-11 | 2021-12-10 | Anti-pd-l1 immunoconjugates, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023552790A JP2023552790A (ja) | 2023-12-19 |
| JPWO2022125908A5 true JPWO2022125908A5 (https=) | 2024-12-11 |
| JP2023552790A5 JP2023552790A5 (https=) | 2024-12-11 |
Family
ID=79288110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534646A Pending JP2023552790A (ja) | 2020-12-11 | 2021-12-10 | 抗ｐｄ－ｌ１イムノコンジュゲート、及びそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240033370A1 (https=) |
| EP (1) | EP4259209A1 (https=) |
| JP (1) | JP2023552790A (https=) |
| KR (1) | KR20230118149A (https=) |
| CN (1) | CN116723866A (https=) |
| AU (1) | AU2021398552A1 (https=) |
| CA (1) | CA3200168A1 (https=) |
| IL (1) | IL303491A (https=) |
| WO (1) | WO2022125908A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118475372A (zh) * | 2021-10-29 | 2024-08-09 | 博尔特生物治疗药物有限公司 | 具有半胱氨酸突变抗体的tlr激动剂免疫缀合物及其用途 |
| WO2024173387A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| CA2399940A1 (en) | 2000-04-13 | 2001-10-25 | The Rockefeller University | Enhancement of antibody-mediated immune responses |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| WO2006073921A2 (en) | 2004-12-30 | 2006-07-13 | The Rockefeller University | Compositions and methods for enhanced dendritic cell maturation and function |
| US20080286819A1 (en) | 2005-11-07 | 2008-11-20 | Ravetch Jeffrey V | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof |
| EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| MX2010003718A (es) | 2007-10-19 | 2010-04-21 | Genentech Inc | Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo. |
| JP5889912B2 (ja) | 2010-11-17 | 2016-03-22 | ジェネンテック， インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
| US9676863B2 (en) | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| AU2017259654B2 (en) * | 2016-05-06 | 2020-02-27 | Shanghai De Novo Pharmatech Co., Ltd. | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof |
| WO2018140831A2 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| US20200113912A1 (en) * | 2018-09-12 | 2020-04-16 | Silverback Therapeutics, Inc. | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates |
| AU2020291014B2 (en) * | 2019-06-13 | 2025-06-05 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
| WO2020252254A1 (en) * | 2019-06-13 | 2020-12-17 | Bolt Biotherapeutics, Inc. | Macromolecule-supported aminobenzazepine compounds |
| CN115996756A (zh) * | 2020-05-08 | 2023-04-21 | 博尔特生物治疗药物有限公司 | 弹性蛋白酶底物肽连接子免疫缀合物及其用途 |
| US20220195066A1 (en) * | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
-
2021
- 2021-12-10 WO PCT/US2021/062824 patent/WO2022125908A1/en not_active Ceased
- 2021-12-10 EP EP21840291.5A patent/EP4259209A1/en active Pending
- 2021-12-10 JP JP2023534646A patent/JP2023552790A/ja active Pending
- 2021-12-10 KR KR1020237022941A patent/KR20230118149A/ko active Pending
- 2021-12-10 AU AU2021398552A patent/AU2021398552A1/en active Pending
- 2021-12-10 US US18/038,910 patent/US20240033370A1/en active Pending
- 2021-12-10 CN CN202180080177.5A patent/CN116723866A/zh active Pending
- 2021-12-10 IL IL303491A patent/IL303491A/en unknown
- 2021-12-10 CA CA3200168A patent/CA3200168A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024059609A5 (https=) | ||
| CA3044898C (en) | Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof | |
| JP2024521629A (ja) | 抗体薬物コンジュゲート、及びその調製方法及びその使用 | |
| JPWO2020252294A5 (https=) | ||
| JP2020019787A5 (https=) | ||
| CN118829450A (zh) | 一种依喜替康衍生物-抗体偶联物及其医药用途 | |
| IL312845B2 (en) | Extacan derivatives, charge-linkers, and their conjugates | |
| JPWO2019213005A5 (https=) | ||
| JP2020531430A (ja) | 抗体を標的とする抗ｃｔｌａ４プロボディ療法 | |
| JPWO2021226440A5 (https=) | ||
| JPWO2022022508A5 (https=) | ||
| JPWO2021067242A5 (https=) | ||
| JPWO2021081407A5 (https=) | ||
| JPWO2022125908A5 (https=) | ||
| JPWO2022087243A5 (https=) | ||
| JPWO2022272039A5 (https=) | ||
| CN107583058A (zh) | 一种t‑2毒素‑抗体缀合物及其用途 | |
| JPWO2022125884A5 (ja) | 抗ｃｅａ免疫複合体、及びその使用 | |
| JPWO2022125904A5 (https=) | ||
| JPWO2022125915A5 (https=) | ||
| JPWO2022125891A5 (https=) | ||
| JPWO2022204536A5 (https=) | ||
| JP7760124B2 (ja) | フタロシアニン染料と抗体又はペプチドとのコンジュゲート | |
| JPWO2023186015A5 (https=) | ||
| JPWO2023154307A5 (https=) |